Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Novoeight® (antihemophilic factor, recombinant) logo
Important Safety Information | Patient Site
Prescribing Information
  • About Novoeight®
  • Efficacy & Safety
  • Dosing & Administration
  • Cost & Coverage
Novoeight® (antihemophilic factor, recombinant) logo

For on-demand bleed control, surgery and routine prophylaxis in adults and children with hemophilia A.

Prescribing Information
Important Safety Information | Patient Site

Financial programs and support for patients

Novo Nordisk provides assistance through NovoCare®, a network to help your patients access co-pay savings, product support, and more.

NovoCare

NovoCare® is designed for your patients

Patients can access: 

  • Product support programs that help with treatment costs
  • Representatives who speak Spanish to better serve more patients

You can help your patients by calling 1-844-668-6732 or have them contact NovoCare® at NovoCare.com   


NovoCare® can help with:

QuickCheck™ benefits verification

Verify your patients’ benefits and receive confirmation of coverage. If no coverage is available, names of alternative therapies may be supplied.

Patient Assistance Program (PAP)

See if your patients are eligible to receive their treatment free of charge. No registration or monthly fees required.

Eligibility and restrictions apply.

Patient Trial Program

Find out if your patients qualify to receive a limited supply of Novo Nordisk’s product for free.

Eligibility and restrictions apply.

Patient
enrollment form

Download and complete the patient enrollment form to attest your patient’s need for treatment.

Go to resources

Additional resources for patients

Co-pay Assistance Program
website
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Co-pay Assistance Program
Direct your patients to our program to find out if they’re eligible for a lower copay with a savings offer.
Visit website

Interim Product Program

Interim Product Program

This limited program provides hemophilia therapy to qualifying patients during a coverage gap. Contact a NovoCare® Specialist by calling 1-844-668-6732.

Looking for other Novoeight® resources?

Selected Important Safety Information for Novoeight®

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment

Indications and Usage

Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Novoeight® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment
  • Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight® in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors

Adverse Reactions

  • The most frequently reported adverse reactions (≥1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia.

Please click here for Novoeight® Prescribing Information.

Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

Novoeight® and Esperoct® are registered trademarks of Novo Nordisk Health Care AG.
NovoCare® is a registered trademark and novoMEDLINK™ and QuickCheck™ are trademarks of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2024 Novo Nordisk All rights reserved. US23NEGT00009  April 2024

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials